Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
February 11, 2024 at 12:40 PM EST
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 million.
